Eli Lilly and Company (NYSE:LLY) Trading 4.7% Higher – Time to Buy?

Eli Lilly and Company (NYSE:LLY)’s share price shot up 4.7% on Monday . The stock traded as high as $1,064.45 and last traded at $1,057.3840. 4,759,020 shares traded hands during mid-day trading, an increase of 40% from the average session volume of 3,406,404 shares. The stock had previously closed at $1,009.52.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Head‑to‑head trial: Novo Nordisk said its next‑gen obesity drug failed to show non‑inferiority to Lilly’s tirzepatide in an 84‑week study, boosting confidence that Lilly’s products remain best‑in‑class for weight loss. Novo Nordisk’s obesity drug falls short against Eli Lilly’s in Copenhagen trial
• Positive Sentiment: Regulatory/product expansion: The FDA approved a four‑dose single‑patient KwikPen for Zepbound, giving patients a one‑month, multi‑dose option at the same self‑pay price — a clear convenience play that can help retention and adherence. Eli Lilly’s Zepbound Gets FDA OK for Multi-Dose Pen
• Positive Sentiment: Commercial rollout: Lilly launched the Zepbound KwikPen (monthly, $299 self‑pay option highlighted), which reduces friction for patients and may limit churn vs. single‑dose formats — supportive for revenue and margins. Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen
• Positive Sentiment: Pipeline synergy: Lilly reported positive trial data showing Taltz (ixekizumab) plus Zepbound outperformed Taltz alone in adults with plaque psoriasis who are overweight — evidence that tirzepatide may have broader clinical synergies and uses. Eli Lilly (LLY) Expands Pipeline With Positive Trial Data and New Licensing Deal
• Positive Sentiment: Institutional flows: Reports show hedge funds and large ETFs increased exposure to mega‑caps including Eli Lilly, which can amplify upward moves in the stock. Hedge Funds’ Mag 7, Eli Lilly Buying Spree Sparks Massive ETF Accumulation In IVV, SPY, QQQ
• Neutral Sentiment: Retention strategy: Coverage notes Lilly is betting the multi‑dose pen will improve patient retention and reduce device waste — strategically valuable but execution and payor response will determine magnitude of benefit. Eli Lilly bets on multi-dose Zepbound pen in GLP-1 retention push
• Negative Sentiment: Insider/ownership notes: Publicized data show significant institutional and Endowment sales over the past quarters (large share movements by Lilly Endowment and others); heavy insider/institutional selling could be watched by investors as a potential risk factor. Eli Lilly rises as rival obesity-drug trial data strengthen tirzepatide’s edge

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft boosted their price target on Eli Lilly and Company from $1,200.00 to $1,285.00 and gave the company a “buy” rating in a report on Monday, February 9th. CICC Research raised their target price on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research report on Wednesday, February 11th. Wolfe Research boosted their price target on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. Bank of America decreased their price objective on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a report on Monday, December 15th. Finally, Barclays assumed coverage on Eli Lilly and Company in a research report on Thursday. They issued an “overweight” rating and a $1,350.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,228.54.

Eli Lilly and Company Price Performance

The company’s 50 day moving average is $1,054.83 and its 200-day moving average is $917.84. The firm has a market capitalization of $997.49 billion, a price-to-earnings ratio of 46.07, a P/E/G ratio of 1.17 and a beta of 0.39. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. During the same period last year, the firm posted $5.32 earnings per share. The business’s revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, February 13th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s payout ratio is currently 30.15%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of LLY. Maryland Capital Advisors Inc. acquired a new position in Eli Lilly and Company in the 4th quarter valued at $25,000. Basso Capital Management L.P. acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth $30,000. Miller Global Investments LLC bought a new stake in shares of Eli Lilly and Company in the fourth quarter valued at about $33,000. E Fund Management Hong Kong Co. Ltd. increased its position in Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after acquiring an additional 24 shares during the period. Finally, Dorato Capital Management acquired a new stake in Eli Lilly and Company in the 4th quarter worth about $36,000. 82.53% of the stock is owned by institutional investors.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.